{"id":"01eea241-8b2a-46e5-bdcd-e09761c61c28","name":"Neuralink","slug":"neuralink","description":"Neuralink is a brain-computer interface (BCI) company founded by Elon Musk in 2016, developing implantable brain chips that enable people with paralysis to control computers and devices with their thoughts. The company's N1 Implant is surgically placed by the R1 Robot, and its PRIME Study began first-in-human trials in January 2024 with patient Noland Arbaugh. Neuralink received FDA Breakthrough Device designation, implanted devices in approximately a dozen patients by late 2025, and raised approximately $1.85B in total funding including a $650M Series E at a $9.6B valuation.","status":null,"founded":2016,"hq":"Fremont, CA, USA","fundingTotal":"650000000","type":"hardware","reviewStatus":"reviewed","sources":[{"url":"https://neuralink.com/","title":"Neuralink - Pioneering Brain Computer Interfaces","sourceName":"Neuralink"}],"keyFacts":[{"label":"Founder","value":"Elon Musk"},{"label":"Total funding","value":"approximately $1.85B ($650M Series E at $9.6B valuation)"},{"label":"Products","value":"N1 Implant (brain chip), R1 Robot (surgical robot)"},{"label":"Clinical trial","value":"PRIME Study (NCT06429735, first-in-human)"},{"label":"FDA","value":"Breakthrough Device designation"},{"label":"First patient","value":"Noland Arbaugh (January 2024)"},{"label":"Patients","value":"approximately 12 implanted by late 2025"}],"aliases":[],"collisionRisk":"low","reviewNote":null,"atsProvider":null,"atsSlug":null,"createdAt":"2026-07-06T07:11:01.869Z","updatedAt":"2026-07-06T07:12:33.663Z","jsonLd":{"@context":"https://schema.org","@type":"Organization","@id":"https://registry.deploy.report/companies/neuralink","url":"https://registry.deploy.report/companies/neuralink","name":"Neuralink","description":"Neuralink is a brain-computer interface (BCI) company founded by Elon Musk in 2016, developing implantable brain chips that enable people with paralysis to control computers and devices with their thoughts. The company's N1 Implant is surgically placed by the R1 Robot, and its PRIME Study began first-in-human trials in January 2024 with patient Noland Arbaugh. Neuralink received FDA Breakthrough Device designation, implanted devices in approximately a dozen patients by late 2025, and raised approximately $1.85B in total funding including a $650M Series E at a $9.6B valuation.","identifier":"01eea241-8b2a-46e5-bdcd-e09761c61c28","foundingDate":"2016","address":"Fremont, CA, USA","publisher":{"@id":"https://deploy.report/#organization"}},"framework_metadata":{"framework_schema_version":"0.1.0","verification_status":"verified","maturity_stage":null,"lifecycle_state":null,"architectural_position":{"cohort":null,"sub_cohorts":[]},"within_cohort_verified_vs_claimed_pair":null,"cap_flags":[],"verification_depth":{"sources_count":1,"primary_source_types":[]}}}